Creative Planning raised its position in shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) by 5.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,863 shares of the biotechnology company’s stock after buying an additional 3,000 shares during the period. Creative Planning’s holdings in ZIOPHARM Oncology were worth $379,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in ZIOP. Norges Bank acquired a new position in ZIOPHARM Oncology during the fourth quarter worth $5,556,000. Vident Investment Advisory LLC raised its position in ZIOPHARM Oncology by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 137,976 shares of the biotechnology company’s stock worth $875,000 after buying an additional 22,996 shares during the period. Highbridge Capital Management LLC acquired a new position in ZIOPHARM Oncology during the fourth quarter worth $164,000. Old West Investment Management LLC acquired a new position in ZIOPHARM Oncology during the first quarter worth $205,000. Finally, Morgan Stanley raised its position in ZIOPHARM Oncology by 19.5% in the first quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock worth $12,610,000 after buying an additional 324,774 shares during the period. 38.17% of the stock is currently owned by hedge funds and other institutional investors.
Shares of ZIOPHARM Oncology Inc (NASDAQ ZIOP) traded down 3.11% during mid-day trading on Friday, hitting $4.99. 1,324,948 shares of the stock traded hands. ZIOPHARM Oncology Inc has a 1-year low of $4.84 and a 1-year high of $7.88. The company’s 50-day moving average price is $5.79 and its 200 day moving average price is $6.32. The company’s market capitalization is $701.75 million.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. The business’s revenue for the quarter was down 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.01) EPS. Equities research analysts forecast that ZIOPHARM Oncology Inc will post ($0.56) EPS for the current fiscal year.
WARNING: “ZIOPHARM Oncology Inc (ZIOP) Shares Bought by Creative Planning” was first posted by BNB Daily and is the sole property of of BNB Daily. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/creative-planning-increases-position-in-ziopharm-oncology-inc-ziop-updated-updated.html.
A number of research analysts have weighed in on ZIOP shares. HC Wainwright initiated coverage on shares of ZIOPHARM Oncology in a research note on Thursday, June 1st. They issued a “buy” rating and a $9.50 price objective on the stock. BidaskClub upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, April 26th. Finally, ValuEngine upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $13.17.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.